OPKO Health, Inc. (NASDAQ:OPK) Stake Reduced by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP lowered its holdings in OPKO Health, Inc. (NASDAQ:OPK) by 9.1% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,654,535 shares of the biotechnology company’s stock after selling 266,901 shares during the period. Dimensional Fund Advisors LP owned about 0.38% of OPKO Health worth $3,319,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in OPK. Y.D. More Investments Ltd acquired a new stake in OPKO Health during the 2nd quarter worth about $1,840,000. AWM Investment Company Inc. grew its holdings in shares of OPKO Health by 18.2% during the 1st quarter. AWM Investment Company Inc. now owns 1,300,000 shares of the biotechnology company’s stock valued at $1,560,000 after acquiring an additional 200,000 shares in the last quarter. PFG Investments LLC increased its stake in shares of OPKO Health by 2.5% in the second quarter. PFG Investments LLC now owns 960,965 shares of the biotechnology company’s stock worth $1,201,000 after acquiring an additional 23,700 shares during the last quarter. Hennion & Walsh Asset Management Inc. raised its holdings in shares of OPKO Health by 11.4% during the first quarter. Hennion & Walsh Asset Management Inc. now owns 776,020 shares of the biotechnology company’s stock worth $931,000 after acquiring an additional 79,525 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its stake in OPKO Health by 4.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 445,981 shares of the biotechnology company’s stock valued at $536,000 after purchasing an additional 17,671 shares in the last quarter. 64.63% of the stock is owned by institutional investors and hedge funds.

OPKO Health Stock Performance

NASDAQ OPK opened at $1.47 on Friday. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.63 and a quick ratio of 1.36. The company’s fifty day moving average is $1.54 and its two-hundred day moving average is $1.39. OPKO Health, Inc. has a 52-week low of $0.85 and a 52-week high of $1.75. The firm has a market capitalization of $1.02 billion, a price-to-earnings ratio of -4.20 and a beta of 1.63.

OPKO Health (NASDAQ:OPK) last announced its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.08. The business had revenue of $182.20 million during the quarter, compared to analysts’ expectations of $184.70 million. OPKO Health had a negative net margin of 33.79% and a negative return on equity of 17.67%. The firm’s revenue for the quarter was down 31.3% on a year-over-year basis. During the same quarter last year, the company posted ($0.03) EPS. Equities research analysts forecast that OPKO Health, Inc. will post -0.29 EPS for the current year.

Analyst Ratings Changes

Several brokerages recently commented on OPK. Piper Sandler reissued an “overweight” rating and issued a $3.00 price target on shares of OPKO Health in a research note on Tuesday, September 17th. HC Wainwright restated a “buy” rating and set a $3.00 price target on shares of OPKO Health in a report on Thursday, September 26th. StockNews.com upgraded shares of OPKO Health to a “sell” rating in a report on Saturday, July 27th. Finally, Barrington Research restated an “outperform” rating and set a $2.25 target price on shares of OPKO Health in a report on Friday, September 20th.

Insider Buying and Selling

In related news, major shareholder Opko Health, Inc. sold 25,000 shares of OPKO Health stock in a transaction on Friday, July 19th. The stock was sold at an average price of $32.29, for a total transaction of $807,250.00. Following the completion of the sale, the insider now directly owns 3,383,403 shares of the company’s stock, valued at $109,250,082.87. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders sold 636,444 shares of company stock worth $21,125,127 in the last quarter. Insiders own 47.26% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.